DK3290052T3 - Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 - Google Patents

Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 Download PDF

Info

Publication number
DK3290052T3
DK3290052T3 DK17191118.3T DK17191118T DK3290052T3 DK 3290052 T3 DK3290052 T3 DK 3290052T3 DK 17191118 T DK17191118 T DK 17191118T DK 3290052 T3 DK3290052 T3 DK 3290052T3
Authority
DK
Denmark
Prior art keywords
growth factor
monoclonal antibodies
antibodies against
factor receptor
fibroblast growth
Prior art date
Application number
DK17191118.3T
Other languages
English (en)
Inventor
Jin Kim Kyung
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Application granted granted Critical
Publication of DK3290052T3 publication Critical patent/DK3290052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
DK17191118.3T 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 DK3290052T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30
EP14188785.1A EP2842573B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to Fibroblast Growth Factor receptor 2

Publications (1)

Publication Number Publication Date
DK3290052T3 true DK3290052T3 (da) 2020-02-03

Family

ID=42153600

Family Applications (3)

Application Number Title Priority Date Filing Date
DK14188785.1T DK2842573T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblast vækstfaktorreceptor 2
DK09825523.5T DK2365828T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2.
DK17191118.3T DK3290052T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK14188785.1T DK2842573T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblast vækstfaktorreceptor 2
DK09825523.5T DK2365828T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2.

Country Status (21)

Country Link
US (8) US8101723B2 (da)
EP (4) EP3290052B1 (da)
JP (7) JP5627591B2 (da)
KR (1) KR101699432B1 (da)
CN (1) CN102131524B (da)
AU (1) AU2009313357B2 (da)
BR (1) BRPI0917315B8 (da)
CA (2) CA2733668C (da)
DK (3) DK2842573T3 (da)
ES (3) ES2523740T3 (da)
HK (3) HK1160012A1 (da)
HR (2) HRP20171640T1 (da)
HU (1) HUE035700T2 (da)
LT (2) LT3290052T (da)
MX (1) MX2011000455A (da)
NO (1) NO2842573T3 (da)
PL (3) PL3290052T3 (da)
PT (3) PT2842573T (da)
RU (1) RU2546254C9 (da)
SI (2) SI2842573T1 (da)
WO (1) WO2010054265A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
ES2523740T3 (es) 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
MX2012013068A (es) * 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anticuerpos anti - fgfr2.
CN103201287B (zh) * 2010-08-12 2016-04-13 艾托生物有限公司 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US20150023989A1 (en) 2011-12-14 2015-01-22 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof
CN104169298B (zh) 2012-03-08 2018-04-20 扬森疫苗与预防公司 可结合并中和b型流感病毒的人类结合分子及其用途
US9714298B2 (en) * 2012-04-09 2017-07-25 Daiichi Sankyo Company, Limited Anti-FGFR2 antibodies and methods of use thereof for treating cancer
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
RS58147B1 (sr) * 2012-12-21 2019-02-28 Janssen Biotech Inc Senzitivni višestruki imunotest za rastvorljive receptore faktora rasta fibroblasta
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP4036118A1 (en) * 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
KR20160066024A (ko) * 2013-10-08 2016-06-09 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
TW201642904A (zh) * 2015-04-08 2016-12-16 第一三共股份有限公司 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
RU2021107536A (ru) * 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
AR112069A1 (es) 2017-06-02 2019-09-18 Ablynx Nv Inmunoglobulinas que fijan aggrecan
AU2018355244A1 (en) 2017-10-24 2020-04-09 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
CN111601616A (zh) 2017-10-24 2020-08-28 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
US20230052680A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
TW202241951A (zh) * 2020-12-29 2022-11-01 大陸商深圳福沃藥業有限公司 抗ｆｇｆｒ２抗體及其用途
WO2023056916A1 (zh) * 2021-10-08 2023-04-13 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2063431C (en) 1989-07-06 2002-10-29 Lewis T. Williams Receptors for fibroblast growth factors
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ATE502646T1 (de) 2002-01-31 2011-04-15 Max Planck Gesellschaft Fgfr agoniste
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
JP4686634B2 (ja) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
AU2007315211B2 (en) * 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
AU2008230880B2 (en) * 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
ES2523740T3 (es) 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
US10689448B2 (en) 2020-06-23
JP6960485B2 (ja) 2021-11-05
PL3290052T3 (pl) 2020-06-29
HUE035700T2 (en) 2018-05-28
US8101723B2 (en) 2012-01-24
HK1249053A1 (zh) 2018-10-26
JP6342223B2 (ja) 2018-06-13
JP6661734B2 (ja) 2020-03-11
US9382324B2 (en) 2016-07-05
US20160362496A1 (en) 2016-12-15
JP5627591B2 (ja) 2014-11-19
EP2842573A1 (en) 2015-03-04
HRP20171640T1 (hr) 2018-01-12
EP3290052B1 (en) 2019-12-25
JP7301106B2 (ja) 2023-06-30
US9834609B2 (en) 2017-12-05
DK2842573T3 (da) 2017-10-30
BRPI0917315A2 (pt) 2015-11-17
CN102131524A (zh) 2011-07-20
JP2020096615A (ja) 2020-06-25
CA2733668C (en) 2022-08-30
US20120134994A1 (en) 2012-05-31
ES2523740T3 (es) 2014-12-01
US20230242650A1 (en) 2023-08-03
NO2842573T3 (da) 2018-02-24
JP6445496B2 (ja) 2018-12-26
US20140193899A1 (en) 2014-07-10
SI3290052T1 (sl) 2020-07-31
BRPI0917315B1 (pt) 2020-12-08
SI2842573T1 (en) 2018-01-31
US20100196364A1 (en) 2010-08-05
PT3290052T (pt) 2020-02-06
RU2546254C2 (ru) 2015-04-10
EP2365828A2 (en) 2011-09-21
JP2012508184A (ja) 2012-04-05
PL2842573T3 (pl) 2018-04-30
AU2009313357B2 (en) 2015-06-11
CA3166399A1 (en) 2010-05-14
KR20110081141A (ko) 2011-07-13
PT2365828E (pt) 2014-12-12
JP2017019807A (ja) 2017-01-26
JP2019052165A (ja) 2019-04-04
CN102131524B (zh) 2014-05-14
US8603987B2 (en) 2013-12-10
WO2010054265A2 (en) 2010-05-14
ES2770134T3 (es) 2020-06-30
DK2365828T3 (da) 2014-12-08
EP3290052A1 (en) 2018-03-07
HRP20200090T1 (hr) 2020-04-03
US20180094063A1 (en) 2018-04-05
EP2842573B1 (en) 2017-09-27
JP2023116746A (ja) 2023-08-22
KR101699432B1 (ko) 2017-01-24
HK1160012A1 (en) 2012-08-10
LT3290052T (lt) 2020-02-25
US10138301B2 (en) 2018-11-27
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
US20200347141A1 (en) 2020-11-05
CA2733668A1 (en) 2010-05-14
ES2646168T3 (es) 2017-12-12
LT2842573T (lt) 2017-12-11
BRPI0917315B8 (pt) 2021-05-25
EP3783024A1 (en) 2021-02-24
JP2022008996A (ja) 2022-01-14
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
PL2365828T3 (pl) 2015-04-30
JP2014240385A (ja) 2014-12-25
EP2365828A4 (en) 2012-06-06
AU2009313357A1 (en) 2010-05-14
HK1207974A1 (en) 2016-02-19
US20190153105A1 (en) 2019-05-23
EP2365828B1 (en) 2014-10-15
WO2010054265A3 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
DK3290052T3 (da) Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0819165A2 (pt) Anticorpos anti-vegf
EP2331579A4 (en) MONOCLONAL ANTIBODIES
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
SG10201601279SA (en) Monoclonal Antibody STRO-4
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
CR20170001A (es) Anticuerpos anti factor d humanizados
IL204536A0 (en) Anti - il -6 receptor antibody
BRPI0923359A2 (pt) Anticorpos anti-igf
NO344963B1 (no) Humanisert antistoff
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0909633A2 (pt) anticorpos anti-tyrp1